PCSK9 and prostate cancer: In recent decades, observational studies investigating the effects of statins and alternate LDL-C-lowering drugs (ezetimibe and PCSK9 inhibitors) on the risks of breast cancer and prostate cancer have yielded inconsistent results [6, 7, 9, 10, 32].